揭示了基于肺表面活性剂的纳米载体在蛋白质吸入治疗中的潜力
Kiramat Ali Shah1, Anam Razzaq1, Bengang You1
1College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
概括
肺表面活性剂涂层增强酶载纳米颗粒的粘液粘附和细胞吸收,以改善肺部药物输送. 这些修改后的纳米颗粒显示了肺内灌注后的精确肺部分布.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术纳米技术
- 肺部药物输送 肺部药物输送
背景情况:
- 聚乳糖糖酸 (PLGA) 纳米颗粒 (NP) 对药物输送具有前景.
- 肺表面活性剂 (PS) 修改可能会提高肺中的NP性能.
研究的目的:
- 研究肺表面活性剂 (PS) 涂层对酶载荷的PLGA纳米粒子 (NP) 的作用.
- 评估PS修改对NP特征,粘液相互作用,细胞吸收和体内肺部分布的影响.
主要方法:
- 装载着酶的PLGANP使用双乳化制造,并通过Box-Behnken实验设计进行优化.
- 在各种PS:PLGA比率下,NP被表面修改为二甲酸胆 (DPPC) 或二甲酸甘油 (DPPG).
- 特性包括尺寸,PDI,泽塔潜力,DL%,EE%,生物活性,药物释放,粘液粘附/透,细胞吸收,毒性,以及在内灌注后的体内肺部分布.
主要成果:
- 修改PS并没有显著改变药物释放或PLGANP的生物活性.
- PS@PLGA NPs表现出改善的粘液粘附,减少粘液透,以及增强的细胞内化.
- 活体和体内研究证实了NP粘结,气道接口层的形成,以及在内心灌注后肺部的精确分布.
结论:
- 肺表面活性剂修饰提供了一个可行的策略,以提高纳米载体的性能,用于肺部药物输送.
- 经过PS修改的PLGANP表现出改善的粘膜粘合特性和细胞吸收,促进向的肺部输送.
- 这项研究为开发有效的肺表面活性剂修饰纳米载体系统提供了指导.
相关概念视频
Inhaled Medications
237
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
237
Breathing
58.5K
The process of breathing, inhaling and exhaling, involves the coordinated movement of the chest wall, the lungs, and the muscles that move them. Two muscle groups with important roles in breathing are the diaphragm, located directly below the lungs, and the intercostal muscles, which lie between the ribs. When the diaphragm contracts, it moves downward, increasing the volume of the thoracic cavity and creating more room for the lungs to expand. When the intercostal muscles contract, the ribs...
58.5K


